Bodyport, a San Francisco, CA-based digital health company focused on the detection and management of heart disease, closed an $11.2m Series A funding round.
The round, which brings total funding to $15.8m, was led by Boehringer Ingelheim Venture Fund with participation from existing investors Playground Global and Initialized Capital, among others. Boehringer Ingelheim Venture Fund’s Dr. Debbie Lin, Playground Global’s Bruce Leak, and Initialized Capital’s Garry Tan will join the board of directors.
The company intends to use the funds to deepen key health partnerships and launch a virtual cardiac clinic that brings intelligent interventions to its remote monitoring technology.
Co-founded by biomedical engineers Corey Centen and Sarah Smith, Bodyport develops a novel biomarker platform that detects early signs of cardiovascular disease, incorporating proprietary sensor technology into a bathroom scale form factor. Rather than relying on wearables, the Bodyport Scale is designed to detect cardiac signals and biomarkers through a user’s feet, powering algorithms that have the potential to predict risk and enable optimized, early interventions. The company is initially focused on improving the management of heart failure. Bodyport also announced today a collaboration with Brigham and Women’s Hospital focused on furthering technology to prevent avoidable hospitalizations and to help discover and develop novel diagnostic biomarkers for the early detection of cardiovascular disease.